Search Browse Earnings

Tempest Therapeutics, Inc. — SlamSEC

Tempest Therapeutics, Inc.

Nasdaq:TPST

Pharmaceutical Preparations·BRISBANE, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$277,000

FY 2017

Adj. EBITDA

-$27.9M

-10061.7% margin

FY 2024

Net Income

-$29.5M

-10646.6% margin

FY 2024

EPS (Diluted)

-$1.91

FY 2024

Stock Price

$2.37

+2.6%

2026-03-09

52W Range

$2.12 – $12.23

P/E Ratio

-1.2x

Market Cap

$10.5M

Cash

$39.2M

FY 2024

Total Debt

$6.4M

FY 2024

Net Cash

$32.8M

FY 2024

Enterprise Value

-$22.3M

Debt / EBITDA

1.2x

FY 2017

EV / EBITDA

0.8x

Employees

—